Rosina T Lis

8PUBLICATIONS
71CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 12, 2026
TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

|Aug 05, 2025
Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer.

Sinead Flanagan, Rosina T Lis, Ying Huang

|Feb 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition.

Scott Wilkinson, Anson T Ku, Rosina T Lis

|Sep 20, 2022
Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.

Konrad H Stopsack, Xiaofeng A Su, J Bailey Vaselkiv

|Mar 01, 2022
Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.

John R Bright, Rosina T Lis, Anson T Ku

|Apr 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.

Rana R McKay, Lucia Kwak, Jett P Crowdis

Pageof 2

Frequent Collaborators

4 joint publications

Adam G Sowalsky

3 joint publications

Scott Wilkinson

3 joint publications

Nicole V Carrabba

3 joint publications

Nicolas T Terrigino